Boston Scientific : BSX Investor Day 2019 Full Presentation

Susan Lisa

Vice President, Investor Relations

Safe harbor for forward-looking statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like

"anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking

statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings "Risk Factors" and "Safe Harbor for Forward-Looking Statements." Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements.

We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Regulatory disclaimers

Product	Regulatory Disclaimer
EXALT™Model D	Not available for sale, currently pending 510(k) clearance in the US.
SpyGlass™Discover	Device under development. Not available for use or sale worldwide.
EXALT™Model B	Device under development. Not available for use or sale worldwide.
EXALT™Model TG	Device under development. Not available for use or sale worldwide.
SpyGlass™DS II	Device under development. Not available for use or sale worldwide.
Cutting Device for Endoluminal Surgery	Device under development. Not available for use or sale worldwide.
Suturing Device for Endoluminal Surgery	Device under development. Not available for use or sale worldwide.
SAVAL™Drug-ElutingBelow-the-Knee Stent	U.S. Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Ranger™Drug-Coated Balloon	CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
IVUS Imaging Catheters for Venous Disease	Device under development. Not available for use or sale worldwide.
High Pressure Balloons for Venous Disease	Device under development. Not available for use or sale worldwide.
Retractable Coil for Interventional Oncology	Device under development. Not available for use or sale worldwide.
EMPOWER™Modular Pacing System	Device under development. Not available for use or sale worldwide.
LUX-Dx™Insertable Cardiac Monitor	Device under development. Not available for use or sale worldwide.
DirectSense™Technology	CE Marked. Not available for use or sale in the U.S.
IntellaNav Stablepoint™Ablation Catheter	Device under development. Not available for use or sale worldwide.
POLARx™Single Shot Cryo Balloon	Device under development. Not available for use or sale worldwide.
LUMININZE™Single Shot RF Balloon	Device under development. Not available for use or sale worldwide.

Regulatory disclaimers

Product	Regulatory Disclaimer
Next Gen SCS System	Device under development. Not available for use or sale worldwide.
Next Gen DBS Programming with Visualization &	Device under development. Not available for use or sale worldwide.
StimView™
Next Gen DBS Platform & Programmer	Device under development. Not available for use or sale worldwide.
Physiology Tablet for Complex PCI	Device under development. Not available for use or sale worldwide.
Comet™II FFR	Device under development. Not available for use or sale worldwide.
SYNERGY™Stent XD, 48mm and MEGATRON™	Device under development. Not available for use or sale worldwide.
Drug-Coasted Balloon for Coronary Therapies	Device under development. Not available for use or sale worldwide.
WACTHMAN FLX™	CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
ACURATE neo™Self-Expanding Valve Platform	CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
ACURATE neo2™Self-Expanding Valve Platform	Pending CE Mark. Not available for use or sale in the U.S.
ACURATE Prime	Device under development. Not available for use or sale worldwide.
Millipede Mitral Repair Technology	Device under development. Not available for use or sale worldwide.
LOTUS Mantra™Valve System	Device under development. Not available for use or sale worldwide.
AngioJet Clothunter™	Device under development. Not available for use or sale worldwide.
CLI Catheter	Device under development. Not available for use or sale worldwide.
POLARx™next gen	Device under development. Not available for use or sale worldwide.
RHYTHMIA™5.0	Device under development. Not available for use or sale worldwide.
RESONATE™2.0	Device under development. Not available for use or sale worldwide.

Financial disclaimers

Market Estimates:

Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

BSX Estimates:

All financial estimates and other projections, including but not limited to pipeline, growth drivers, and investments, as well as other references throughout this document, unless otherwise noted, exclude the proposed acquisition of BTG plc.

Non-GAAP Financial Measures:

This presentation contains non-GAAP measures (denoted with *) in talking about our company's performance. The reconciliations of those non-GAAP measures to their most

comparable GAAP measures are contained within this document including appendices attached to the end of this presentation.

Revenue Growth:

All growth rates are operational unless otherwise noted. Operational growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations. Organic growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the sales from the acquisitions of the American Medical Systems male urology portfolio, EndoChoice Holdings, Inc., Symetis SA, NxThera, Inc., Claret Medical, Inc. and Augmenix, Inc. in the periods for which there are no prior period related sales.

Segment Information:

Effective January 1, 2018, to align the company's business and organizational structure focused on active implantable devices, we created the Rhythm and Neuro segment, which includes Cardiac Rhythm Management (CRM), Electrophysiology and Neuromodulation (previously included in the MedSurg segment). In addition, we combined the Middle East and Africa (MEA) organizations (previously included with Asia-Pacific) with Europe to create the EMEA region. Prior year balances and year over year growth rates have been updated accordingly.

Emerging Markets:

We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.

Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries:

Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. The revision had an immaterial impact on prior year sales.